Jason Butler
Stock Analyst at Citizens
(4.66)
# 176
Out of 5,090 analysts
144
Total ratings
51.7%
Success rate
45.76%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $11.07 | +71.64% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $63.33 | +45.27% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $6.38 | +88.09% | 8 | Oct 9, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $33 → $95 | $114.51 | -17.04% | 4 | Jul 23, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $29.50 | -5.08% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $27.44 | +34.84% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $14.89 | +161.92% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $3.60 | +66.67% | 11 | Jun 12, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $40.05 | +149.69% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $32.02 | +18.68% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $78 | $65.67 | +18.78% | 16 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $8.71 | +106.66% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $3.73 | +7.24% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $901.17 | -22.21% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.89 | +203.03% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $10.42 | -13.63% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.95 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $10.56 | +79.92% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $3.48 | +532.18% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.84 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $12.09 | +347,294.54% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $14.60 | +694.52% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.42 | +103.62% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.67 | - | 1 | Dec 2, 2020 |
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $11.07
Upside: +71.64%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $63.33
Upside: +45.27%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $6.38
Upside: +88.09%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Market Outperform
Price Target: $33 → $95
Current: $114.51
Upside: -17.04%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $29.50
Upside: -5.08%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $27.44
Upside: +34.84%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $14.89
Upside: +161.92%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.60
Upside: +66.67%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $40.05
Upside: +149.69%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $32.02
Upside: +18.68%
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $65.67
Upside: +18.78%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.71
Upside: +106.66%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $3.73
Upside: +7.24%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $901.17
Upside: -22.21%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.89
Upside: +203.03%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $10.42
Upside: -13.63%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.95
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $10.56
Upside: +79.92%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $3.48
Upside: +532.18%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.84
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $12.09
Upside: +347,294.54%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $14.60
Upside: +694.52%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.42
Upside: +103.62%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.67
Upside: -